Addus HomeCare (NASDAQ:ADUS) Stock: Insider David Tucker Sells 14,850 Shares

Addus HomeCare Corporation (NASDAQ:ADUS) EVP David Tucker sold 14,850 shares of the stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $124.75, for a total transaction of $1,852,537.50. Following the completion of the sale, the executive vice president directly owned 8,073 shares of the company’s stock, valued at $1,007,106.75. This represents a 64.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Addus HomeCare Price Performance

NASDAQ ADUS opened at $125.49 on Thursday. Addus HomeCare Corporation has a 12 month low of $87.95 and a 12 month high of $131.59. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of 20.91, a PEG ratio of 1.66 and a beta of 0.75. The company’s 50 day moving average is $118.19 and its two-hundred day moving average is $107.10. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.02.

Addus HomeCare (NASDAQ:ADUS) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.04. The business had revenue of $387.74 million for the quarter, compared to the consensus estimate of $388.72 million. Addus HomeCare had a net margin of 7.39% and a return on equity of 10.22%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.56 earnings per share. As a group, research analysts anticipate that Addus HomeCare Corporation will post 6.41 earnings per share for the current year.

Addus HomeCare News Roundup

Here’s some of the latest news about ADUS:

• Positive Sentiment: TD Cowen raised its price target to $145 and reiterated a Buy rating; Wall Street Zen also upgraded the stock to Strong Buy. The company’s latest reported quarterly EPS of $1.83 topped the $1.79 consensus, while revenue grew 7% year over year, though it narrowly missed estimates.
• Neutral Sentiment: Addus plans to participate in the 2026 Stephens Annual Investment Conference. The announcement offers investor access but provides no new operating or financial guidance. Article: Addus HomeCare to Participate in 2026 Stephens Annual Investment Conference
• Neutral Sentiment: A report claims short interest was zero shares, despite describing it as a large increase. The conflicting wording makes the short-interest update difficult to interpret.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC raised its position in shares of Addus HomeCare by 73.3% during the second quarter. Hsbc Holdings PLC now owns 24,463 shares of the company’s stock valued at $2,446,000 after buying an additional 10,350 shares during the last quarter. Summit Creek Advisors LLC purchased a new position in shares of Addus HomeCare in the second quarter worth $8,552,000. Globeflex Capital L P purchased a new position in shares of Addus HomeCare in the second quarter worth $1,635,000. Bank of America Corp DE boosted its position in shares of Addus HomeCare by 11.3% during the first quarter. Bank of America Corp DE now owns 323,037 shares of the company’s stock worth $30,252,000 after acquiring an additional 32,714 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Addus HomeCare during the second quarter worth $901,000. 95.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ADUS shares. Barclays lifted their target price on shares of Addus HomeCare from $96.00 to $101.00 and gave the company an “underweight” rating in a research note on Wednesday, November 4th. TD Cowen increased their price target on Addus HomeCare from $131.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Citigroup cut Addus HomeCare from a “market outperform” rating to a “neutral” rating in a report on Monday, September 14th. Royal Bank Of Canada raised their price target on Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Finally, Raymond James Financial set a $137.00 price objective on Addus HomeCare in a research report on Monday, September 28th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.70.

About Addus HomeCare

Addus HomeCare Corporation provides home-based care services to older adults and people with disabilities. Its services are designed to help clients receive care at home and in other community-based settings. The company operates through personal care, hospice and home health services. Personal care includes assistance with daily activities; hospice provides end-of-life care and support; and home health offers skilled nursing and therapy services. Founded in 1979, Addus serves communities across multiple states.